Avidity Biosciences Management
Management criteria checks 2/4
Avidity Biosciences' CEO is Sarah Boyce, appointed in Oct 2019, has a tenure of 5.17 years. total yearly compensation is $11.14M, comprised of 5.7% salary and 94.3% bonuses, including company stock and options. directly owns 0.06% of the company’s shares, worth $2.30M. The average tenure of the management team and the board of directors is 3.9 years and 5.3 years respectively.
Key information
Sarah Boyce
Chief executive officer
US$11.1m
Total compensation
| CEO salary percentage | 5.7% |
| CEO tenure | 5.2yrs |
| CEO ownership | 0.06% |
| Management average tenure | 3.9yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term
Oct 02Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders
Aug 16Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67
Aug 14
Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
Aug 11Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade
Jun 14Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
May 19Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Mar 01Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Feb 29Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?
Nov 04Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Apr 08Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Nov 17Avidity slips 20% as FDA places lead asset on partial clinical hold
Sep 27We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Jul 29Avidity stock rises amid Chardan starting coverage with Buy
Jul 20Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides
Jul 12We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely
Mar 26Avidity Biosciences: Risks And Potential
Dec 09We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Nov 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$280m |
| Jun 30 2024 | n/a | n/a | -US$252m |
| Mar 31 2024 | n/a | n/a | -US$229m |
| Dec 31 2023 | US$11m | US$635k | -US$212m |
| Sep 30 2023 | n/a | n/a | -US$202m |
| Jun 30 2023 | n/a | n/a | -US$193m |
| Mar 31 2023 | n/a | n/a | -US$192m |
| Dec 31 2022 | US$5m | US$601k | -US$174m |
| Sep 30 2022 | n/a | n/a | -US$162m |
| Jun 30 2022 | n/a | n/a | -US$148m |
| Mar 31 2022 | n/a | n/a | -US$128m |
| Dec 31 2021 | US$6m | US$570k | -US$118m |
| Sep 30 2021 | n/a | n/a | -US$96m |
| Jun 30 2021 | n/a | n/a | -US$78m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$823k | US$484k | -US$44m |
| Sep 30 2020 | n/a | n/a | -US$38m |
| Jun 30 2020 | n/a | n/a | -US$34m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$4m | US$104k | -US$25m |
Compensation vs Market: Sarah's total compensation ($USD11.14M) is above average for companies of similar size in the US market ($USD6.67M).
Compensation vs Earnings: Sarah's compensation has increased whilst the company is unprofitable.
CEO
Sarah Boyce (52 yo)
5.2yrs
Tenure
US$11,139,719
Compensation
Ms. Sarah Boyce is Director of Abcuro, Inc. from July 2024. She serves as Independent Director of Contineum Therapeutics, Inc Since June 2024. She has been President, Chief Executive Officer and Director a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 12.1yrs | US$260.31k | 0.064% $ 2.4m | |
| President | 5.2yrs | US$11.14m | 0.060% $ 2.3m | |
| Chief Financial & Chief Business Officer | 4.6yrs | US$4.48m | 0.0065% $ 245.6k | |
| Chief Scientific & Technical Officer | 3.9yrs | US$4.89m | 0.072% $ 2.7m | |
| Chief Human Resources Officer | 4.3yrs | US$3.73m | 0.079% $ 3.0m | |
| Distinguished Scientist | 1.8yrs | US$3.03m | 0.13% $ 4.9m | |
| Chief Strategy Officer | less than a year | US$235.31k | 0% $ 0 | |
| Scientific Founder | 12.9yrs | no data | no data | |
| Scientific Founder & Member of Scientific Advisory Board | 12.9yrs | no data | no data | |
| Chief Legal Officer & Corporate Secretary | less than a year | no data | no data | |
| Consultant | less than a year | no data | no data | |
| Chief Program Officer | 1.9yrs | no data | no data |
3.9yrs
Average Tenure
59yo
Average Age
Experienced Management: RNA's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 12.1yrs | US$260.31k | 0.064% $ 2.4m | |
| President | 5.2yrs | US$11.14m | 0.060% $ 2.3m | |
| Distinguished Scientist | 1.8yrs | US$3.03m | 0.13% $ 4.9m | |
| Scientific Founder | no data | no data | no data | |
| Scientific Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.7yrs | US$245.31k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.3yrs | US$244.31k | 0% $ 0 | |
| Observer | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.3yrs | US$245.81k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.3yrs
Average Tenure
58.5yo
Average Age
Experienced Board: RNA's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 12:46 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Avidity Biosciences, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Eric Schmidt | Cantor Fitzgerald & Co. |